Abstract: Described herein is a method of generating a test program structure from test requirement data. The method comprises translating the test requirement data into a form suitable for execution within a test programming environment to generate a hierarchy of sequence files based on user supplied information. The test program comprises a plurality of Test Blocks and each Test Block comprises at least one Test.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Simulation system and method for a reservoir represented by a model having a plurality of matrix nodes, a plurality of fracture nodes, a fracture zone and a fracture-free zone are described. One embodiment includes computer-implemented steps of, for each of a plurality of matrix nodes in interconnected zones, characterizing the matrix nodes as dual matrix nodes or non-dual matrix nodes. Dual matrix nodes may be treated as a block and eliminated, after which the coefficient matrix and RHS vector for the model are updated. In-fill patterns between and among fracture nodes and non-dual matrix nodes resulting from the elimination are determined. For non-dual matrix nodes, the nodes are merged to a fracture grid, after which the coefficient matrix and RHS vector for the model are updated accordingly. The resultant linear system is linearly solved, and backsolving is performed for any eliminated dual matrix nodes.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Systems and methods for parallel incomplete LU (ILU) factorization in distributed sparse linear systems, which order nodes underlying the equations in the system(s) by dividing nodes into interior nodes and boundary nodes and assigning no more than three codes to distinguish the boundary nodes. Each code determines an ordering of the nodes, which in turn determines the order in which the equations will be factored and the solution performed.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: The present invention relates to the diagnosis, prognosis and/or treatment of wound infection by testing wound fluid for the presence of a marker which is present in an amount which is indicative of infection. The marker may be high molecular weight phospholipase A2 (cPLA2) or a marker which is correlated with cPLA2.

Abstract: There is provided a system and method for rule-based dynamic server-side streaming manifest files. There is provided a method comprising receiving a request to provide a first video content for playback, evaluating a plurality of rules for the first video content, generating a dynamic manifest file referencing the first video content, and providing the dynamic manifest file in response to the request, thereby enabling an application to playback the first video content for output on a display by interpreting the dynamic manifest file. The rules may implement various features such as dynamic advertisement insertion, load balancing, client customization, user and device targeting, enhanced security mechanisms, global announcements, and others. As streaming protocols are widely supported by default on many client platforms, the dynamic manifest files can be utilized in a user friendly and transparent manner compared to client-side solutions requiring cumbersome client software installations.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, inter-mixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt in situ. The present application also relates to various compositions obtained from these processes, including crystalline forms.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: An aqueous depilatory composition comprising a thioglycolate salt and a fluoride ion source.

Abstract: A depilatory article comprising a substrate and an aqueous depilatory composition, the aqueous depilatory composition being in physical contact with the substrate, forming a coated area of the substrate and comprising a thioglycolate salt and a phosphate ion source, sulphate or sulphite ion source or mixtures thereof.

Abstract: Machine vibration baselines are synthesized without averaging historical vibration data. Instead machinery configuration information is used, including data about the machine train, the machine's rotating components, and the machine speeds. For each component being considered, a plurality of parameters is identified for deriving baseline portions. The parameters for one component are used to identify baseline vibration amplitude floor values, vibration amplitudes at frequencies corresponding to various harmonics of a rotational speed, and vibration amplitudes corresponding to forcing frequencies and their harmonics/sidebands. Parameters for other components also may be used to identify amplitudes at harmonic frequencies and forcing frequencies.

Abstract: Systems and methods for parallel incomplete LU (ILU) factorization in distributed sparse linear systems, which order nodes underlying the equations in the system(s) by dividing nodes into interior nodes and boundary nodes and assigning no more than three codes to distinguish the boundary nodes. Each code determines an ordering of the nodes, which in turn determines the order in which the equations will be factored and the solution performed.

Abstract: Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

Abstract: Systems and methods for determining active constraints in a surface facility network, which include the use of slack variables and multipliers in system equations to eliminate the extraneous (inactive) constraints.